The ZENITH study looked at some of the sickest pulmonary arterial hypertension (PAH) patients—those labelled as functional class 3...

"A person's mental health significantly influences how they experience pain and suffering associated with chronic disease. It's essential...

We asked Liss Cairns, Program Manager at Plan Institute, some questions about the Disability Tax Credit and the new Canada Disability...

Hello. My name is Denise Rumbolt and I’d like to tell you about my daughter, Candice.  Like any mother, I’ll tell you she’s beautiful,...

This systemic review summarized the data from six studies that examined whether prostacyclin analogues are safe and useful when used to...

Living with a rare disease can feel like walking an unmarked path—isolated, uncertain, and overlooked. For those with pulmonary arterial...

In a small study of 34 pulmonary arterial hypertension (PAH) patients taking triple therapy plus sotatercept, some were able to stop...

My name is Cindy Hayman, and I have been living with Pulmonary Arterial Hypertension (PAH) for the past seven years. I am classified as a...

On May 5, World Pulmonary Hypertension Day , the Pulmonary Hypertension Association of Canada (PHA Canada) is calling for urgent action...

I was diagnosed with Pulmonary Hypertension in 2019.  After tests & procedures, it was determined I likely had group 2 and 3 PH. Group 2...

A 2024 study looked at the association between socioeconomic disadvantage and pulmonary hypertension. In one New York hospital system,...

The 2025 BC Medication Coverage Report  is here—and it reveals serious gaps in access to life-saving medications across the province....

Medications for pulmonary arterial hypertension (PAH) are not approved for use in patients with pulmonary hypertension due to...

The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...

There has been significant progress in making sotatercept available to those who need it. Just two months after Health Canada approved it...

Researchers wanted to know whether an enlarged pulmonary artery could independently predict risk in pulmonary arterial hypertension (in...

Tax season is upon us! The pulmonary hypertension community brought two tips to our attention. First, the usual disclaimer: we are not...

Seralutinib is a molecule that blocks inflammation, cell proliferation, and scarring responsible for pulmonary arterial hypertension. The...

New Report Sheds Light on Pulmonary Hypertension in Canada Respiplus has just released a groundbreaking report, A Canadian Initiative:...

Many people know about Canada’s Disability Tax Credit, but did you know that there is also a non-refundable tax credit for caregivers? If...